Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
New onset diabetes after transplantation (NODAT) is a frequent and feared complication after
kidney transplantation and leads to an increase in cardiovascular complications as well as in
the rate of graft loss. Very little data exist on how patients in which NODAT has been
diagnosed should be treated. It is suspected that Cylosporine A (Sandimmun, TM) is less
diabetogenic than Tacrolimus (Prograf, TM). Furthermore, it has been described that early
initiation of insulin treatment in Diabetes mellitus type 2 can preserve and improve the
function of the insulin secreting cells in the pancreas. Therefore, the investigators test
the effects of conversion from Tacrolimus to Cyclosporine A in patients with newly diagnosed
NODAT who have just started early treatment with insulin. The hypothesis is that patients who
are treated with insulin and who are switched to Cyclosporine A have improved glucose
metabolism compared to patients who are treated with insulin and who remain on Tacrolimus
therapy.